

WEST Search History


[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, September 14, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	(548/\$7.ccls. or 546/274\$3.ccls. or 544/215.ccls. or 544/216.ccls.) and (ethylamine or (ethyl adj amine))	4046

END OF SEARCH HISTORY

११



```

REP G1=(0-1) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT      IS MCY   AT   12
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RSPEC      1
NUMBER OF NODES IS  12

STEREO ATTRIBUTES:  NONE

```

```
=> s ll ful
FULL SEARCH INITIATED 12:53:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 751732 TO ITERATE
```

```
100.0% PROCESSED    751732 ITERATIONS
SEARCH TIME: 00.00.12
```

292 ANSWERS

L3 292 SEA SSS FUL L1

=> s l3 and (imidaz? or triazol? or pyrimid?)
1160481 IMIDAZ?
642169 TRIAZOL?
1242201 PYRIMID?
L15 59 L3 AND (IMIDAZ? OR TRIAZOL? OR PYRIMID?)

=> s l3 not l15
L16 233 L3 NOT L15

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.72	267.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.00

FILE 'CAPLUS' ENTERED AT 13:06:08 ON 14 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 13 Sep 2006 (20060913/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l16
L17 47 L16
=> s l17 not l9
L18 42 L17 NOT L9

=> d hitstr 42

L18 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
IT 86615-88-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of)
RN 86615-88-5 CAPLUS
CN Ethanamine, 2-[4-[(2-methyl-1,3-dioxolan-2-yl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



=> d hitstr 41

L18 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 92787-62-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with piperidinylbis(phenoxyethyl hydroxysuccinimide))

RN 92787-62-7 CAPLUS

CN Ethanamine, 2,2'-[(1-ethyl-4-piperidinylidene)bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



=> d hitstr 40

L18 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 92787-62-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction with benzylchloroformate)

RN 92787-62-7 CAPLUS

CN Ethanamine, 2,2'-[(1-ethyl-4-piperidinylidene)bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




IT 105708-05-2

(condensation of, with chlorothienopyrimidine)

RN 105708-05-2 CAPLUS

CN Ethanamine, 2-[4-(1,3-dioxolan-2-ylmethyl)-2-methylphenoxy]- (9CI) (CA
INDEX NAME)




IT 119670-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of hypoglycemic and hypolipemic thiazolidinedione derivs.)

RN 119670-22-3 CAPLUS

CN	2,4-Thiazolidinedione, 5-[[4-(2-aminoethoxy)phenyl]methyl]- (9CI)	(CA
	INDEX NAME)	



```
=> d hitstr 37
```


L18 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 117826-24-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antithrombotic)

RN 117826-24-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)phenyl]-4,5-dihydro- (9CI) (CA
INDEX NAME)



```
=> d hitstr 36
```


L18 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 133155-44-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for cardiotonic and β -blocker)

RN 133155-44-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)-3-methylphenyl]- (9CI) (CA INDEX NAME)




IT 117826-24-1 133155-50-7 133155-51-8

133155-52-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of cardiogenic and β -blocker)


RN 117826-24-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)phenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 133155-50-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)-3-methylphenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 133155-51-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)-3-chlorophenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 133155-52-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)phenyl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



=> d hitstr 35

L18 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 171095-78-6P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(1; preparation of platelet-activating factor receptor antagonists for the treatment of cardiovascular, inflammatory and immune disorders)

RN 171095-78-6 CAPLUS

CN Ethanamine, 2-[2-methoxy-6-(methylsulfonyl)-4-[(2R,5R)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 34

L18 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 171095-78-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(2,5-diaryltetrahydrofurans as PAF receptor antagonists and 5-lipoxygenase inhibitors)

RN 171095-78-6 CAPLUS

CN Ethanamine, 2-[2-methoxy-6-(methylsulfonyl)-4-[(2R,5R)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 33


L18 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 172353-57-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrazolylphenyl pivalates as elastase inhibitors)

RN 172353-57-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[4-(2-aminoethoxy)phenyl]methyl]-2H-tetrazol-5-yl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d hitstr 32

L18 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 173528-82-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (heterocyclylmethyl)phenol ethers having juvenile hormone-like activity as insect growth regulators)

RN 173528-82-0 CAPLUS

CN Ethanamine, 2-[4-(1H-pyrazol-1-ylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



=> d hitstr 31

L18 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 188128-47-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridylmethylphenyl derivs. as antihyperlipemics)

RN 188128-47-4 CAPLUS

CN Ethanamine, 2-[4-(3-pyridinylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



=> d hitstr 30

L18 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 188867-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)

RN 188867-39-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-(2-aminoethoxy)phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 29

L18 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 189130-77-6P


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of novel cyclic depsipeptide PF1022 derivs. as anthelmintics)

RN 189130-77-6 CAPLUS

CN Cyclo[(α R)-4-(2-aminoethoxy)- α -hydroxybenzenepropanoyl-N-methyl-L-leucyl-(2R)-2-hydroxypropanoyl-N-methyl-L-leucyl-(α R)- α -hydroxybenzenepropanoyl-N-methyl-L-leucyl-(2R)-2-hydroxypropanoyl-N-methyl-L-leucyl], monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



O=

● HCl



IT 189158-51-8P, PF 1022-278


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of novel cyclic depsipeptide PF1022 derivs. as anthelmintics)

RN 189158-51-8 CAPLUS

CN Cyclo[(α R)-4-(2-aminoethoxy)- α -hydroxybenzenepropanoyl-N-methyl-L-leucyl-(2R)-2-hydroxypropanoyl-N-methyl-L-leucyl-(α R)- α -hydroxybenzenepropanoyl-N-methyl-L-leucyl-(2R)-2-hydroxypropanoyl-N-methyl-L-leucyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 189130-89-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel cyclic depsipeptide PF1022 derivs. as anthelmintics)



RN 189130-89-0 CAPLUS

CN Cyclo[(αR)-4-(2-aminoethoxy)-α-hydroxybenzenepropanoyl-N-methyl-L-leucyl-(2R)-2-hydroxypropanoyl-N-methyl-L-leucyl-(αR)-4-(2-aminoethoxy)-α-hydroxybenzenepropanoyl-N-methyl-L-leucyl-(2R)-2-hydroxypropanoyl-N-methyl-L-leucyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



O=



=> d hitstr 28

L18 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 119670-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(solid-phase preparation of hybrid thiazolidinedione-fatty acid PPAR γ ligands)

RN 119670-22-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(2-aminoethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



=> d hitstr 27

L18 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 211494-78-9P 211495-22-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted 2-amino-6-(4-hydroxyphenyl)pyridines as nitric oxide synthase (NOS) inhibitors)


RN 211494-78-9 CAPLUS

CN Phenol, 5-(2-aminoethoxy)-2-(6-amino-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 211495-22-6 CAPLUS

CN 2-Pyridinamine, 6-[4-(2-aminoethoxy)-2,6-dimethylphenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 26

L18 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 188867-39-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(piperidine renin inhibitors)

RN 188867-39-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-(2-aminoethoxy)phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 25

L18 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 292615-89-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of lipoic acid amides and analogs as PPAR γ agonists)

RN 292615-89-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(2-aminoethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d hitstr 24

L18 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 211495-22-6 310433-32-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(nitric oxide synthase inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm)


RN 211495-22-6 CAPLUS

CN 2-Pyridinamine, 6-[4-(2-aminoethoxy)-2,6-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 310433-32-0 CAPLUS

CN 2-Pyridinamine, 6-[4-(2-aminoethoxy)-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 23

L18 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 313681-88-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylsulfonamides as inhibitors of HIV aspartyl protease and antiviral agents)

RN 313681-88-8 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-[[4-(2-aminoethoxy)phenyl]methyl]-5-[[[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]methyl]-2,2-dimethyl-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, (4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 292615-89-5, 5-[4-(2-Aminoethoxy)benzyl]thiazolidine-2,4-dione
hydrochloride

(precursor; preparation of novel pyrimidine-, quinazoline-, and purine-based thiazolidinedione derivs. as antidiabetic agents)

CN 2,4-Thiazolidinedione, 5-[[4-(2-aminoethoxy)phenyl]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




```
=> d hitstr 21
```

IT 292615-89-5, 5-[[4-(2-Aminoethoxy)phenyl]methyl]-1,3-thiazolidine-
2,4-dione hydrochloride

(preparation of dithiolanyl thiazolidinediones as peroxisome proliferator-activated receptor γ activators)

CN 2,4-Thiazolidinedione, 5-[[4-(2-aminoethoxy)phenyl]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d hitstr 20

L18 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 171095-78-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,5-diaryltetrahydrofurans as PAF receptor antagonists and 5-lipoxygenase inhibitors)

RN 171095-78-6 CAPLUS

CN Ethanamine, 2-[2-methoxy-6-(methylsulfonyl)-4-[(2R,5R)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 19

L18 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 188867-39-2P, 1-Piperidinecarboxylic acid, 4-[4-(2-aminoethoxy)phenyl]-3-(2-naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel-

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-alkoxy piperidines and -azabicyclooctanes)

RN 188867-39-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-(2-aminoethoxy)phenyl]-3-(2-

naphthalenylmethoxy)-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d hitstr 18

L18 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 416859-73-9P, 2-(4-Oxazol-4-ylphenoxy)ethylamine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(process for preparation of azolylphenoxyethylaminopyridinylethanols via fermentation of pyridinylbromoethanone to bromopyridinylethanol using

Absidia

cylindrospora ATCC 22751)

RN 416859-73-9 CAPLUS

CN Ethanamine, 2-[4-(4-oxazolyl)phenoxy]- (9CI) (CA INDEX NAME)



=> d hitstr 17

L18 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 602313-22-4P, 2-[4-[6-Amino-5-(4-fluorobenzoyl)-2-oxo-1(2H)-pyridinyl]-3,5-difluorophenoxy]ethanaminium chloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of amino(monocyclic aroyl)pyridinones that inhibit p38 map kinase for use as antiinflammatory agents)

RN 602313-22-4 CAPLUS

CN 2(1H)-Pyridinone, 6-amino-1-[4-(2-aminoethoxy)-2,6-difluorophenyl]-5-(4-fluorobenzoyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> d hitstr 16

L18 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 620628-32-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spirobarbituric acid derivs. useful as inhibitors of matrix metalloproteases)

RN 620628-32-2 CAPLUS

CN 2,2-Pyrrolidinedicarboxylic acid, 1-[4-(2-aminoethoxy)phenyl]-5-oxo-, diethyl ester (9CI) (CA INDEX NAME)



=> d hitstr 15

L18 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 679434-53-8 679434-61-8

RL: PAC (Pharmacological activity); BIOL (Biological study)

(structure-based drug design targeting an inactive RNA conformation in relation to exploiting the flexibility of HIV-1 TAR RNA)


RN 679434-53-8 CAPLUS

CN Guanidine, [4-[[[2-(2-aminoethoxy)-5-(3-thienyl)phenyl]methyl]amino]butyl]- (9CI) (CA INDEX NAME)



RN 679434-61-8 CAPLUS

CN 4-Piperidinemethanamine, N-[[2-(2-aminoethoxy)-5-(2-pyridinyl)phenyl]methyl]-(9CI) (CA INDEX NAME)



=> d hitstr 14

L18 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 666841-87-8P 666841-91-4P 666841-93-6P

666842-49-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzylpyrazolyl glucopyranosides and galactopyranosides as sodium-glucose cotransporter (SGLT1) inhibitors for prevention or treatment of diseases attributable to hyperglycemia or galactosemia)

RN 666841-87-8 CAPLUS

CN β -D-Glucopyranoside, 4-[[4-(2-aminoethoxy)phenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 666841-91-4 CAPLUS

CN β -D-Glucopyranoside, 4-[[4-(2-aminoethoxy)-2-methylphenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 666841-93-6 CAPLUS

CN β -D-Glucopyranoside, 4-[[4-(2-aminoethoxy)phenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 666842-49-5 CAPLUS

CN β -D-Glucopyranoside, 4-[[4-(2-aminoethoxy)-2-methylphenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 13

L18 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 705445-30-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(SGLT1 inhibitors as preventives or remedies for diseases caused by hyperglycemia)

RN 705445-30-3 CAPLUS

CN β -D-Glucopyranoside, 4-[[4-(2-aminoethoxy)-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 12

L18 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 705933-40-0P 705933-49-9P 705933-55-7P

705933-62-6P 705933-71-7P 705933-78-4P


705933-86-4P 705934-12-9P 705934-20-9P

705934-32-3P 705935-38-2P 705935-39-3P
705935-72-4P 705935-73-5P 705935-76-8P
705935-85-9P 705937-03-7P 705937-04-8P
705937-12-8P 705938-12-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705933-40-0 CAPLUS


CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(1-methylethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705933-49-9 CAPLUS


CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(1-methylethyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 705933-55-7 CAPLUS


CN 1H-Pyrazol-3-amine, 5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705933-62-6 CAPLUS


CN Ethanamine, 2-[4-[3-chloro-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705933-71-7 CAPLUS

CN Ethanamine, 2-[4-[3-chloro-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 705933-78-4 CAPLUS
CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(1-methylethoxy)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705933-86-4 CAPLUS
CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(1-methylethoxy)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705934-12-9 CAPLUS
CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705934-20-9 CAPLUS

CN Ethanamine, 2-[4-[1-(1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)



RN 705934-32-3 CAPLUS


CN Ethanamine, 2-[4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-38-2 CAPLUS


CN 1-Propanone, 1-[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-39-3 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705935-72-4 CAPLUS

CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 705935-73-5 CAPLUS
 CN Ethanamine, 2-[4-[3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705935-76-8 CAPLUS
 CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(methylsulfonyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 705935-85-9 CAPLUS
 CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 705937-03-7 CAPLUS


CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(1-methylethenyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 705937-04-8 CAPLUS

CN Ethanamine, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-12-8 CAPLUS
 CN Ethanamine, 2-[4-[1-[4-(methylthio)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705938-12-1 CAPLUS
 CN Urea, N'-[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 705935-37-1P 705935-40-6P 705935-41-7P
 705935-42-8P 705935-74-6P 705935-75-7P
 705935-84-8P 705936-02-3P 705936-03-4P
 705936-95-4P 705937-05-9P 705937-06-0P
 705937-07-1P 705937-08-2P 705937-09-3P
 705937-10-6P 705937-11-7P 705937-13-9P
 705937-14-0P 705937-15-1P 705937-16-2P
 705937-17-3P 705937-18-4P 705937-19-5P
 705937-20-8P 705937-21-9P 705937-22-0P
 705937-31-1P 705937-32-2P 705937-33-3P
 705938-13-2P 705938-14-3P 705939-51-1P
 705939-76-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705935-37-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[4-(2-aminoethoxy)phenyl]-N-ethyl-1-(4-methoxyphenyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-40-6 CAPLUS


CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]cyclopropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-41-7 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 5-[4-(2-aminoethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 705935-42-8 CAPLUS


CN 1-Propanone, 1-[5-[4-(2-aminoethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-3-yl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 705935-74-6 CAPLUS

CN Ethanamine, 2-[4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)



RN 705935-75-7 CAPLUS


CN Ethanamine, 2-[4-[1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-84-8 CAPLUS

CN Ethanamine, 2-[4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 705936-02-3 CAPLUS

CN Ethanamine, 2-[4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-


yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705936-03-4 CAPLUS


CN Ethanamine, 2-[4-[1-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705936-95-4 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-3-yl]cyclopropyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-05-9 CAPLUS
 CN Ethanamine, 2-[4-[3-ethoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-06-0 CAPLUS
 CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(2-methylpropoxy)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-07-1 CAPLUS
CN Ethanamine, 2-[4-[3-(2-methoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-08-2 CAPLUS
CN Ethanamine, 2-[4-[3-(2-ethoxyethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705937-09-3 CAPLUS
CN Ethanamine, 2-[4-[3-methoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 705937-10-6 CAPLUS


CN Ethanamine, 2-[4-[3-ethoxy-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705937-11-7 CAPLUS

CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-4-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-13-9 CAPLUS
 CN Ethanamine, 2-[4-[3-(difluoromethyl)-1-[4-(methylthio)phenyl]-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-14-0 CAPLUS
 CN Ethanamine, 2-[4-[3-cyclopropyl-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 705937-15-1 CAPLUS
 CN Piperidine, 1-[[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-16-2 CAPLUS
 CN Piperidine, 1-[[5-[4-(2-aminoethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705937-17-3 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 5-[4-(2-aminoethoxy)phenyl]-N-ethyl-1-(6-methoxy-3-pyridinyl)-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 705937-18-4 CAPLUS


CN Ethanamine, 2-[4-[3-(cyclopentyloxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705937-19-5 CAPLUS

CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705937-20-8 CAPLUS
 CN Ethanamine, 2-[4-[3-(2,2-difluoroethoxy)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705937-21-9 CAPLUS
 CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 705937-22-0 CAPLUS


CN Ethanamine, 2-[4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 705937-31-1 CAPLUS


CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-4-methyl-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705937-32-2 CAPLUS


CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-4-methyl-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 705937-33-3 CAPLUS


CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(methylthio)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705938-13-2 CAPLUS


CN Urea, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705938-14-3 CAPLUS


CN Acetamide, 2-[[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705939-51-1 CAPLUS

CN Ethanamine, 2-[4-[1-[4-(phenylmethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705939-76-0 CAPLUS
 CN Ethanamine, 2-[4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)



=> d hitstr 11


L18 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 705933-40-0P 705933-49-9P 705933-55-7P
 705933-62-6P 705933-71-7P 705933-78-4P
 705933-86-4P 705934-12-9P 705934-20-9P
 705934-32-3P 705935-38-2P 705935-39-3P
 705935-72-4P 705935-73-5P 705935-76-8P
 705935-85-9P 705937-03-7P 705937-04-8P
 705937-12-8P 705938-12-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705933-40-0 CAPLUS


CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(1-methylethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705933-49-9 CAPLUS


CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(1-methylethyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 705933-55-7 CAPLUS


CN 1H-Pyrazol-3-amine, 5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705933-62-6 CAPLUS


CN Ethanamine, 2-[4-[3-chloro-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705933-71-7 CAPLUS


CN Ethanamine, 2-[4-[3-chloro-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 705933-78-4 CAPLUS

CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(1-methylethoxy)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705933-86-4 CAPLUS
 CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(1-methylethoxy)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705934-12-9 CAPLUS
 CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705934-20-9 CAPLUS

CN Ethanamine, 2-[4-[1-(1,3-benzodioxol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)



RN 705934-32-3 CAPLUS


CN Ethanamine, 2-[4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705935-38-2 CAPLUS

CN 1-Propanone, 1-[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705935-39-3 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705935-72-4 CAPLUS
CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 705935-73-5 CAPLUS
CN Ethanamine, 2-[4-[3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 705935-76-8 CAPLUS
 CN Ethanamine, 2-[4-[1-(4-methoxyphenyl)-3-(methylethylamino)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 705935-85-9 CAPLUS
 CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 705937-03-7 CAPLUS
 CN Ethanamine, 2-[4-[1-(6-methoxy-3-pyridinyl)-3-(1-methylethenyl)-1H-pyrazol-5-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 705937-04-8 CAPLUS
 CN Ethanamine, 2-[4-[3-methoxy-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 705937-12-8 CAPLUS
 CN Ethanamine, 2-[4-[1-[4-(methylthio)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705938-12-1 CAPLUS

CN Urea, N'-[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 705935-37-1P 705935-40-6P 705935-41-7P
 705935-42-8P 705935-74-6P 705935-75-7P
 705935-84-8P 705936-02-3P 705936-03-4P
 705936-95-4P 705937-05-9P 705937-06-0P
 705937-07-1P 705937-08-2P 705937-09-3P
 705937-10-6P 705937-11-7P 705937-13-9P
 705937-14-0P 705937-15-1P 705937-16-2P
 705937-17-3P 705937-18-4P 705937-19-5P
 705937-20-8P 705937-21-9P 705937-22-0P
 705937-31-1P 705937-32-2P 705937-33-3P
 705938-13-2P 705938-14-3P 705939-51-1P
 705939-76-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. useful as COX-1 inhibitors)

RN 705935-37-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-[4-(2-aminoethoxy)phenyl]-N-ethyl-1-(4-methoxyphenyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-40-6 CAPLUS


CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]cyclopropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705935-41-7 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-[4-(2-aminoethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 705935-42-8 CAPLUS

CN 1-Propanone, 1-[5-[4-(2-aminoethoxy)phenyl]-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-3-yl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

<-----User Break----->

RN 705938-13-2 CAPLUS


CN Urea, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705938-14-3 CAPLUS


CN Acetamide, 2-[[5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705939-51-1 CAPLUS


CN Ethanamine, 2-[4-[1-[4-(phenylmethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 705939-76-0 CAPLUS

CN Ethanamine, 2-[4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy]- (9CI) (CA INDEX NAME)



=>

=> d hitstr 10

L18 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 735265-22-2P, 2-[4-[2-(Difluoromethyl)-4-(4-methoxyphenyl)-1,3-oxazol-5-yl]phenoxy]ethanamine 735265-32-4P, 5-[4-(2-Aminoethoxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazole-2-carboxamide 735265-47-1P, 2-[4-[2-(Difluoromethyl)-4-(6-methoxy-3-pyridinyl)-1,3-oxazol-5-yl]phenoxy]ethylamine 735265-56-2P, 2-[4-[4-(4-Methoxyphenyl)-2-(trifluoromethyl)-1,3-oxazol-5-yl]phenoxy]ethanamine 735265-66-4P, 2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(trifluoromethyl)-1,3-oxazol-5-yl]phenoxy]ethylamine 735265-75-5P, 2-[4-[2-Isopropyl-4-(4-methoxyphenyl)-1,3-oxazol-5-yl]phenoxy]ethylamine 735266-15-6P, 2-[4-[2-(Difluoromethyl)-5-(4-methoxyphenyl)-1,3-oxazol-4-yl]phenoxy]ethanamine hydrochloride 735266-38-3P, 2-[4-[2-Isopropyl-4-(6-methoxy-3-pyridinyl)-1,3-oxazol-5-yl]phenoxy]ethylamine 735266-48-5P, 2-[4-[2-Cyclopropyl-4-(4-methoxyphenyl)-1,3-oxazol-5-yl]phenoxy]ethylamine 735266-57-6P, 2-[4-[2-Cyclopropyl-4-(6-methoxy-3-pyridinyl)-1,3-oxazol-5-yl]phenoxy]ethylamine 735266-84-9P, 5-[4-(2-Aminoethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)-1,3-oxazole-2-carbonitrile 735267-15-9P, [2-[4-[2-Methoxy-4-(4-methoxyphenyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine 735267-32-0P, [2-[4-[4-(4-Methoxyphenyl)-2-(methylthio)-1,3-oxazol-5-yl]phenoxy]ethyl]amine 735267-38-6P, [2-[4-[4-(4-Methoxyphenyl)-2-(methylthio)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride 735267-41-1P, [2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride 735267-54-6P, 1-[5-[4-(2-Aminoethoxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazol-2-yl]-3-methyl-1-butanone hydrochloride 735267-60-4P, [2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride 735267-88-6P, 5-[4-(2-Aminoethoxy)phenyl]-N,N-diethyl-4-(6-methoxy-3-pyridinyl)-1,3-oxazole-2-carboxamide hydrochloride 735268-08-3P, N-[[5-[4-(2-Aminoethoxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazol-2-yl]methyl]propanamide 735268-18-5P, [2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(methylthio)-1,3-oxazol-5-yl]phenoxy]ethyl]amine 735268-22-1P, N'-[[5-[4-(2-Aminoethoxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazol-2-yl]methyl]-N,N-dimethylurea 735268-23-2P, Methyl [[5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazol-2-yl]methyl]carbamate 735268-40-3P, [2-[4-[4-(6-Methoxy-3-pyridinyl)-2-[(4-pyridinylthio)methyl]-1,3-oxazol-5-yl]phenoxy]ethyl]amine 735268-53-8P, [2-[4-[4-(6-Methoxy-3-pyridinyl)-2-[(2-pyridinylthio)methyl]-1,3-oxazol-5-yl]phenoxy]ethyl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of diaryl-substituted oxazole derivs. as selective COX-I inhibitors for use as analgesics)

RN 735265-22-2 CAPLUS


CN Ethanamine, 2-[4-[2-(difluoromethyl)-4-(4-methoxyphenyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)



H₂N-CH₂-CH₂-O

RN 735265-32-4 CAPLUS


CN 2-Oxazolecarboxamide, 5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



H₂N-CH₂-CH₂-O

RN 735265-47-1 CAPLUS


CN Ethanamine, 2-[4-[2-(difluoromethyl)-4-(6-methoxy-3-pyridinyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)




H₂N-CH₂-CH₂-O

RN 735265-56-2 CAPLUS


CN Ethanamine, 2-[4-[4-(4-methoxyphenyl)-2-(trifluoromethyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 735265-66-4 CAPLUS
 CN Ethanamine, 2-[4-[4-(6-methoxy-3-pyridinyl)-2-(trifluoromethyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 735265-75-5 CAPLUS
 CN Ethanamine, 2-[4-[4-(4-methoxyphenyl)-2-(1-methylethyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 735266-15-6 CAPLUS
 CN Ethanamine, 2-[4-[2-(difluoromethyl)-5-(4-methoxyphenyl)-4-oxazolyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 735266-38-3 CAPLUS

CN Ethanamine, 2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-methylethyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 735266-48-5 CAPLUS

CN Ethanamine, 2-[4-[2-cyclopropyl-4-(4-methoxyphenyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 735266-57-6 CAPLUS


CN Ethanamine, 2-[4-[2-cyclopropyl-4-(6-methoxy-3-pyridinyl)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 735266-84-9 CAPLUS
 CN 2-Oxazolecarbonitrile, 5-[4-(2-aminoethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 735267-15-9 CAPLUS
 CN Ethanamine, 2-[4-[2-methoxy-4-(4-methoxyphenyl)-5-oxazolyl]phenoxy]- (9CI)
 (CA INDEX NAME)




RN 735267-32-0 CAPLUS
 CN Ethanamine, 2-[4-[4-(4-methoxyphenyl)-2-(methylthio)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 735267-38-6 CAPLUS


CN Ethanamine, 2-[4-[4-(4-methoxyphenyl)-2-(methylthio)-5-oxazolyl]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 735267-41-1 CAPLUS


CN Piperidine, 1-[[5-[4-(2-aminoethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 735267-54-6 CAPLUS


CN 1-Butanone, 1-[5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 735267-60-4 CAPLUS


CN Piperidine, 1-[[5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 735267-88-6 CAPLUS


CN 2-Oxazolecarboxamide, 5-[4-(2-aminoethoxy)phenyl]-N,N-diethyl-4-(6-methoxy-3-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 735268-08-3 CAPLUS

CN Propanamide, N-[[5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]methyl]- (9CI) (CA INDEX NAME)




RN 735268-18-5 CAPLUS

CN Ethanamine, 2-[4-[4-(6-methoxy-3-pyridinyl)-2-(methylthio)-5-oxazolyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 735268-22-1 CAPLUS

CN Urea, N'-[[5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 735268-23-2 CAPLUS


CN Carbamic acid, [[5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

<-----User Break----->


=> d hitstr 9

L18 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 211495-22-6 310433-32-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (new pharmaceutical combinations of nitric oxide synthase inhibitors
 and NK-1 receptor antagonists and selective serotonin reuptake
 inhibitors for treatment of disorders facilitated by altering circadian
 rhythms)
 RN 211495-22-6 CAPLUS
 CN 2-Pyridinamine, 6-[4-(2-aminoethoxy)-2,6-dimethylphenyl]- (9CI) (CA INDEX
 NAME)




RN 310433-32-0 CAPLUS
 CN 2-Pyridinamine, 6-[4-(2-aminoethoxy)-2-methoxyphenyl]- (9CI) (CA INDEX
 NAME)



=> d hitstr 8

L18 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 857278-23-0P, Benzyl (3R,4R)-4-[4-(2-aminoethoxy)phenyl]-3-[[4-(3-
 methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-
 carboxylate 857278-25-2P, Benzyl (3R,4R)-4-[4-(2-
 aminoethoxy)phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-
 benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of piperidines as renin inhibitors useful against hypertension
 and other disorders)
 RN 857278-23-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-(2-aminoethoxy)phenyl]-3-[[3,4-dihydro-4-
 (3-methoxypropyl)-2H-1,4-benzoxazin-6-yl]methoxy]-, phenylmethyl ester,
 (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857278-25-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-(2-aminoethoxy)phenyl]-3-[[3,4-dihydro-4-(3-methoxypropyl)-3-oxo-2H-1,4-benzoxazin-6-yl]methoxy]-, phenylmethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 7


L18 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 861966-98-5P 861966-99-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophene and furan compds. for potentiating glutamate receptor function)

RN 861966-98-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[4-(2-aminoethoxy)phenyl]-4-cyano-5-(methylthio)-, ethyl ester (9CI) (CA INDEX NAME)




RN 861966-99-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[4-(2-aminoethoxy)phenyl]-4-cyano-5-(methylthio)-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 861966-98-5


CMF C17 H18 N2 O3 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



=> d hitstr 6

L18 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 864756-94-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridone and related compds. as melanin concentrating hormone

receptor antagonists for treatment of diabetes, obesity, etc.)

RN 864756-94-5 CAPLUS

CN 2(1H)-Pyridinone, 1-[4-(2-aminoethoxy)phenyl]-4-[(4-fluorophenyl)methoxy]- (9CI) (CA INDEX NAME)



=> d hitstr 5

L18 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 872326-22-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, DNA binding affinity, and anticancer activity of diarylpyrazines starting from dichloropyrazine)

RN 872326-22-2 CAPLUS

CN Phenol, 4-[6-[4-(2-aminoethoxy)phenyl]pyrazinyl]- (9CI) (CA INDEX NAME)



=> d hitstr 4

L18 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 869664-49-3P, N-[1-[4-(2-Aminoethoxy)phenyl]-3-tert-butyl-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-methylpyridin-4-yl)oxy]phenyl]urea
869664-55-1P, N-[1-[4-(2-Aminoethoxy)phenyl]-3-tert-butyl-1H-pyrazol-5-yl]-N'-[4-(pyridin-4-yloxy)phenyl]urea 869664-57-3P,
N-[1-[4-(2-Aminoethoxy)phenyl]-3-tert-butyl-1H-pyrazol-5-yl]-N'-[4-(pyridin-3-yloxy)phenyl]urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyl urea derivs. as TrkA kinase inhibitors useful in treatment of cancer)


RN 869664-49-3 CAPLUS

CN Urea, N-[1-[4-(2-aminoethoxy)phenyl]-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 869664-55-1 CAPLUS

CN Urea, N-[1-[4-(2-aminoethoxy)phenyl]-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 869664-57-3 CAPLUS

CN Urea, N-[1-[4-(2-aminoethoxy)phenyl]-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



=> s hitstr 3

0 HITSTR

6679103 3

L19 0 HITSTR 3

(HITSTR(W) 3)

=> d hitstr 3

L19 HAS NO ANSWERS

L19 0 SEA FILE=CAPLUS HITSTR 3

=> d hitstr 118 3

L18 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN

IT 879892-60-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyridinone derivs. and their use as pos. allosteric modulators of mGluR2-receptors for treatment of various neurol. and psychiatric disorders)

RN 879892-60-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[4-(2-aminoethoxy)phenyl]-1-[(4-chloro-2-

fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



=> d hitstr 118 2

L18 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 133155-51-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxopyridazinyl derivs. with mixed pde-inhibitory and β -adrenergic antagonist or partial agonist activity for treatment of heart failure)

RN 133155-51-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-aminoethoxy)-3-chlorophenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



=> d hitstr 118 1

L18 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN


IT 292615-89-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(design and synthesis of dithiolane thiazolidinedione- and phenylacetic acid-based PPAR γ agonists)

RN 292615-89-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(2-aminoethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl